MALIGNANT SOLID TUMORS
Clinical trials for MALIGNANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for MALIGNANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for CML patients: asciminib trial targets treatment failures
Disease control Recruiting nowThis phase 2 study tests asciminib, a daily pill, in 40 adults with chronic myeloid leukemia whose first treatment with a TKI drug didn't work or caused side effects. Participants take asciminib for up to 2 years. The main goal is to see how many achieve a major molecular respons…
Matched conditions: MALIGNANT SOLID TUMORS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cancer drug TAK-505 enters first human trials
Disease control Recruiting nowThis study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…
Matched conditions: MALIGNANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called SHR-4849 combined with other cancer medicines in people with advanced solid tumors. The goal is to see if the combination is safe and can shrink tumors. About 120 adults aged 18 to 75 with measurable tumors and good organ function will take part…
Matched conditions: MALIGNANT SOLID TUMORS
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing an experimental drug called SHR-7787 combined with other anti-cancer medicines in 400 people with advanced solid tumors that cannot be removed by surgery. The goal is to find safe doses and see if the combination can shrink tumors or slow cancer growth. Part…
Matched conditions: MALIGNANT SOLID TUMORS
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for advanced cancer: experimental drug SHR-1681 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called SHR-1681 in 300 people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and how…
Matched conditions: MALIGNANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New MRI scan could sharpen cancer detection
Diagnosis Recruiting nowThis study is testing whether a new MRI technique using a substance called hyperpolarized pyruvate gives consistent results in people with solid tumors. About 109 participants will have two special MRI scans to see if the images are reproducible. The goal is to improve how doctor…
Matched conditions: MALIGNANT SOLID TUMORS
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
Massive study aims to unlock secrets of rare cancers
Knowledge-focused Recruiting nowThis study is collecting medical information and biological samples from up to 10,000 people with rare solid tumors, their relatives, and those with genetic mutations that raise cancer risk. Researchers hope to learn how these tumors develop and change over time. The goal is to i…
Matched conditions: MALIGNANT SOLID TUMORS
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC